Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)
 
 • Company Description   
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Number of Employees: 169

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.20 Daily Weekly Monthly
20 Day Moving Average: 1,322,680 shares
Shares Outstanding: 30.47 (millions)
Market Capitalization: $493.55 (millions)
Beta: 1.12
52 Week High: $72.37
52 Week Low: $9.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.18% 0.48%
12 Week 11.88% 7.24%
Year To Date 2.34% -10.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1050 WALTHAM STREET SUITE 302
-
LEXINGTON,MA 02421
USA		 ph: 617-314-6297
fax: -		 jfrantz@kerostx.com http://www.kerostx.com
 
 • General Corporate Information   
Officers
Jasbir Seehra - Chief Executive Officer
Keith Regnante - Chief Financial Officer
Jean-Jacques Bienaime - Director
Nima Farzan - Director
Carl Gordon - Director

Peer Information
Keros Therapeutics, Inc. (CORR.)
Keros Therapeutics, Inc. (RSPI)
Keros Therapeutics, Inc. (CGXP)
Keros Therapeutics, Inc. (BGEN)
Keros Therapeutics, Inc. (GTBP)
Keros Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 492327101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 30.47
Most Recent Split Date: (:1)
Beta: 1.12
Market Capitalization: $493.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.53 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 23.60% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 10.55
Trailing 12 Months: 10.52
PEG Ratio: 0.45
Price Ratios
Price/Book: 0.70
Price/Cash Flow: -
Price / Sales: 2.00
EPS Growth
vs. Year Ago Period: 87.23%
vs. Previous Quarter: 76.32%
Sales Growth
vs. Year Ago Period: 3,575.77%
vs. Previous Quarter: -21.50%
ROE
09/30/25 - 9.51
06/30/25 - 2.96
03/31/25 - 0.75
ROA
09/30/25 - 8.89
06/30/25 - 2.74
03/31/25 - 0.69
Current Ratio
09/30/25 - 29.86
06/30/25 - 21.11
03/31/25 - 19.29
Quick Ratio
09/30/25 - 29.86
06/30/25 - 21.11
03/31/25 - 19.29
Operating Margin
09/30/25 - 26.12
06/30/25 - 8.06
03/31/25 - 1.96
Net Margin
09/30/25 - 26.12
06/30/25 - 8.06
03/31/25 - 1.96
Pre-Tax Margin
09/30/25 - 28.84
06/30/25 - 11.55
03/31/25 - 6.78
Book Value
09/30/25 - 23.09
06/30/25 - 17.40
03/31/25 - 17.95
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©